169 related articles for article (PubMed ID: 817771)
1. Evidence for familial immune defect in meningococcal meningitis.
Whittle HC; Oduloju A; Evans-Jones G; Greenwood BM
Br Med J; 1976 May; 1(6020):1247-50. PubMed ID: 817771
[TBL] [Abstract][Full Text] [Related]
2. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
3. Complement deficiency and antibody profile in survivors of meningococcal meningitis due to common serogroups in Italy.
D'Amelio R; Agostoni A; Biselli R; Brai M; Caruso G; Cicardi M; Corvetta A; Fontana L; Misiano G; Perricone R
Scand J Immunol; 1992 May; 35(5):589-95. PubMed ID: 1579859
[TBL] [Abstract][Full Text] [Related]
4. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria.
Sanborn WR; Bencić Z; Cvjetanović B; Gotschlich EC; Pollock TM; Sippel JE
Prog Immunobiol Stand; 1971; 5():497-505. PubMed ID: 4633977
[No Abstract] [Full Text] [Related]
5. Recurrent meningococcal meningitis due to partial complement defects and poor anti-meningococcal antibody response.
Herva E; Leinonen M; Käyhty H; Mäkelä PH; Vetoniemi-Korhonen SL
J Infect; 1983 Jan; 6(1):55-60. PubMed ID: 6411822
[TBL] [Abstract][Full Text] [Related]
6. Measurement of growth-inhibiting (bactericidal) antibodies in patients with meningococcal meningitis and in subjects immunized with meningococcal polysaccharide vaccine by a [3H]thymidine assay.
Hassan-King M; Greenwood BM; Whittle HC
J Clin Microbiol; 1985 Jul; 22(1):136-8. PubMed ID: 3926814
[TBL] [Abstract][Full Text] [Related]
7. Latex agglutination test for measurement of antibodies to meningococcal polysaccharides.
Tramont EC; Artenstein MS
Infect Immun; 1972 Mar; 5(3):346-51. PubMed ID: 4629077
[TBL] [Abstract][Full Text] [Related]
8. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
10. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine.
Rosenqvist E; Tjade T; Frøholm LO; Frasch CE
NIPH Ann; 1983 Dec; 6(2):139-49. PubMed ID: 6427704
[TBL] [Abstract][Full Text] [Related]
11. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.
Wahdan MH; Rizk F; el-Akkad AM; el-Ghoroury AA; Hablas R; Girgis NI; Amer A; Boctar W; Sippel JE; Gotschlich EC; Triau R; Sanborn WR; Cvjetanović B
Bull World Health Organ; 1973 Jun; 48(6):667-73. PubMed ID: 4206451
[TBL] [Abstract][Full Text] [Related]
12. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
Wahdan MH; Sallam SA; Hassan MN; Abdel Gawad A; Rakha AS; Sippel JE; Hablas R; Sanborn WR; Kassem NM; Riad SM; Cvjetanović B
Bull World Health Organ; 1977; 55(6):645-51. PubMed ID: 413639
[TBL] [Abstract][Full Text] [Related]
13. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine.
Jennings HJ; Roy R; Gamian A
J Immunol; 1986 Sep; 137(5):1708-13. PubMed ID: 3091688
[TBL] [Abstract][Full Text] [Related]
14. Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate.
Beuvery EC; Miedema F; van Delft RW; Haverkamp J; Tiesjema RH; Nagel J
J Infect; 1983 May; 6(3):247-55. PubMed ID: 6411824
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
16. Control of meningococcal infection in the African meningitis belt by selective vaccination.
Greenwood BM; Wali SS
Lancet; 1980 Apr; 1(8171):729-32. PubMed ID: 6103155
[TBL] [Abstract][Full Text] [Related]
17. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
18. Response of children to Neisseria meningitidis polysaccharide vaccines.
Monto AS; Brandt BL; Artenstein MS
J Infect Dis; 1973 Apr; 127(4):394-400. PubMed ID: 4632878
[No Abstract] [Full Text] [Related]
19. Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination.
Mohammed I; Onyemelukwe GC; Obineche EN; Gupta N; Oyeyinka GO
J Infect; 1984 Sep; 9(2):197-202. PubMed ID: 6438245
[TBL] [Abstract][Full Text] [Related]
20. Dot-immunobinding assay with a monoclonal antibody for detection of group B meningococcal antigen.
Coll P; Borche L; Ausina V; Mirelis B; Prats G
Eur J Clin Microbiol; 1986 Feb; 5(1):44-6. PubMed ID: 3084244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
